Robert Martell, M.D., Ph.D.

Chief Scientific Officer

Dr. Martell is Chief Scientific Officer at Curis, having previously served as Head of Research and Development. Prior to joining the company in 2018, he served on Curis’s Board of Directors. Prior to Curis, he was Chief Medical Officer of Tesaro and MethylGene and held previous leadership positions at Bristol-Myers Squibb and Bayer. In addition, Dr. Martell is co-founder of Epi-Cure Pharmaceuticals, and serves on the Board of Directors of Indaptus Therapeutics. He is a part-time treating physician at Champlain Valley Hematology Oncology and was previously a part-time treating physician at Tufts Medical Center in the Hematology/Oncology Division. Dr. Martell received a B.A. in chemistry from Kalamazoo College, a Ph.D. in Pharmacology from University of Michigan, and an M.D. from Wayne State University. He served on the faculty at Duke University Medical Center and at Yale University School of Medicine after completing his residency and fellowship in Medical Oncology at Duke.